What InCarda Therapeutics does

InCarda Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company founded in 2009 and headquartered in West Jordan, Utah, with a wholly-owned Australian subsidiary in Melbourne. The company is developing novel pharmacological therapies for cardioversion of paroxysmal atrial fibrillation (AF) and atrial flutter (AFL), targeting rapid and safe restoration of normal sinus rhythm. Its core technology pairs Class I-C and Class III antiarrhythmic agents in a synergistic combination designed to maximize cardioversion rates while reducing proarrhythmic risk compared to single-agent therapy. The pipeline consists of two lead programs: an intravenous (IV) Fixed Dose Combination for medically supervised hospital cardioversion, currently in a planned Phase 1 study to confirm safety, PK/PD, and reduced proarrhythmic risk; and a Home Cardioversion Program for self-administered at-home use, currently in preclinical development.

InCarda's go-to-market strategy is structured around two distinct care settings. In the hospital channel, the IV Fixed Dose Combination is positioned for inpatient and outpatient cardioversion, distributed via hospital formularies and pharmacy channels upon regulatory approval. In the at-home channel, the company is developing a self-administered therapy intended to enable earlier discharge, reduce hospital burden, and expand treatment access. The company engages with healthcare providers through medical publications, cardiology conferences, and direct clinical operations outreach rather than consumer marketing. Future revenue is expected to derive from FDA-approved pharmaceutical products sold to hospital systems and, potentially, dispensed directly to eligible patients for at-home use.

The company is venture-backed, having raised approximately $77.9 million across multiple funding rounds between 2012 and 2020, with investors including Innoviva, Deerfield Management, OrbiMed, HealthCap, Sofinnova Partners, Morningside Private Investors, AMV, and 5Y Capital. Leadership comprises a CEO (Dr. Myles Greenberg), CMO (Dr. Luiz Belardinelli), CFO (Carol Manchester, CPA), CTO (Carlos Schuler, PhD), and CBO (Narsi Rangachari), supported by dedicated heads of Regulatory, Clinical Operations, and CMC. InCarda remains pre-revenue with no approved products, and its primary value drivers are clinical trial readouts and eventual regulatory milestones rather than current commercial sales.

Name

InCarda Therapeutics

Legal name

InCarda Therapeutics, Inc.

Website

https://incardatherapeutics.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

InCarda Therapeutics is a clinical-stage biopharmaceutical company developing synergistic Class I-C and Class III antiarrhythmic drug combinations for rapid cardioversion of paroxysmal atrial fibrillation and atrial flutter, with an IV hospital program in Phase 1 and a preclinical at-home self-administration program.

Ownership category

akta.pro rank

Product category

Cardiovascular Pharmaceuticals

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)

Keywords

• Atrial fibrillation therapy
• Antiarrhythmic drug development
• Cardioversion pharmaceuticals
• Inhaled cardiovascular drugs
• Hospital cardiac therapeutics

Headquarters

HQ city

Newark

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Revenue: Pre-revenue biopharmaceutical company developing novel atrial fibrillation cardioversion therapies. Revenue will be generated from FDA-approved pharmaceutical products for hospital-based and at-home cardioversion treatment once clinical development is completed.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

InCarda Therapeutics is a clinical-stage biopharmaceutical company developing prescription drug therapies for atrial fibrillation (AFib) and atrial flutter (AFL) cardioversion. Its pipeline centers on a synergistic combination of Class I-C and Class III antiarrhythmic agents delivered as an IV fixed-dose combination for hospital cardioversion and as an at-home self-administered therapy, designed to restore normal sinus rhythm rapidly while reducing proarrhythmic risk.

Product overview

InCarda Therapeutics is developing a pipeline of innovative drug therapies for atrial fibrillation treatment, consisting of two core product candidates: an IV Fixed Dose Combination for medically supervised hospital cardioversion (currently in Phase 1 clinical development) and a Home Cardioversion Program for at-home self-administration (currently in preclinical development). Both products leverage synergistic combinations of Class I-C and Class III antiarrhythmic drugs to restore normal sinus rhythm, with the hospital program targeting inpatient and outpatient settings while the home program expands treatment access beyond clinical environments.

Differentiator

Problem solved

Functional benefit

Products and services

• IV Fixed Dose Combination (In-Hospital Cardioversion Therapy) Intravenous fixed-dose combination therapy pairing Class I-C and Class III antiarrhythmics for rapid, safe, and effective cardioversion of paroxysmal atrial fibrillation and atrial flutter in medically supervised hospital settings. Currently in Phase 1 clinical development.
• Home Cardioversion Program (At-Home Self-Administered Therapy) Self-administered antiarrhythmic therapy designed to enable patients to convert atrial fibrillation to normal sinus rhythm at home without leaving their residence, expanding treatment access beyond clinical environments. Currently in preclinical development.

Quantifiable outcome

• Maximizes cardioversion rates in paroxysmal AFib and AFL
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• AnGes MG: Clinical-stage Japanese biopharma developing cardiovascular therapies including gene-based approaches. Comparable as a small, cardiovascular-focused clinical developer.
• BioCardia: Clinical-stage cell therapy company with cardiovascular programs. Comparable as a small, clinical-stage cardiovascular developer pursuing novel mechanisms.
• Espero BioPharma: Emerging cardiovascular pharmaceutical company developing therapies for atrial fibrillation and other cardiovascular conditions. Comparable as a smaller, AFib-focused clinical-stage peer.
• Armaron Bio: Australia-based clinical-stage company developing cardioprotective therapies, including approaches targeting AFib. Comparable as a small, Australia-affiliated cardiovascular developer.
• Omeicos Therapeutics: Clinical-stage company developing small-molecule omega-3 epoxyeicosanoid analogs for cardiovascular indications including AFib. Comparable in therapeutic area and clinical maturity.
• Faraday Pharmaceuticals: Clinical-stage company developing FDY-5301 for cardiac protection and indications including AFib. Comparable as a venture-backed cardiovascular developer in similar clinical stage.

Direct peers

• Acesion Pharma: Denmark-based clinical-stage company developing SK channel inhibitors for atrial fibrillation. Comparable as a focused, venture-backed AFib antiarrhythmic developer.
• Correvio Pharma (now AOP Orphan Pharmaceuticals): Specialty cardiovascular company that commercialized Brinavess (vernakalant), an IV antiarrhythmic for rapid AFib cardioversion. Closest precedent for an IV pharmacologic AFib cardioversion launch.
• Milestone Pharmaceuticals: Clinical-stage company developing etripamil, a nasal spray calcium channel blocker for rapid cardioversion of PSVT and potentially AFib. Direct peer in the antiarrhythmic, patient-administered cardioversion space.

Broad incumbents

• HUYA Bioscience International: Broader biopharma company with cardiovascular programs and global development partnerships. Comparable as a cardiovascular-focused specialty pharma, though operating at a wider portfolio level.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/incarda-therapeutics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles24 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InCarda Therapeutics